Last reviewed · How we verify
Live Smallpox Vaccine
Live Smallpox Vaccine stimulates adaptive immune responses by introducing live attenuated vaccinia virus to generate protective antibodies and cell-mediated immunity against smallpox.
Live Smallpox Vaccine stimulates immune response by introducing live attenuated vaccinia virus to generate protective antibodies and cell-mediated immunity against smallpox. Used for Smallpox prevention in at-risk populations, Post-exposure prophylaxis following smallpox exposure.
At a glance
| Generic name | Live Smallpox Vaccine |
|---|---|
| Sponsor | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" |
| Drug class | Live attenuated vaccine |
| Target | Vaccinia virus antigens (envelope and intracellular proteins) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains live vaccinia virus, a related orthopoxvirus that cross-protects against smallpox infection. Upon administration, the virus replicates in host cells, triggering both humoral (antibody) and cellular (T-cell) immune responses. This generates immunological memory that prevents or significantly reduces severity of smallpox infection upon exposure to the natural virus.
Approved indications
- Smallpox prevention and post-exposure prophylaxis
- Biodefense/emergency preparedness against smallpox
Common side effects
- Vaccination site reaction (erythema, edema, pustule formation)
- Fever
- Myalgia/malaise
- Lymphadenopathy
- Serious adverse events (myocarditis, encephalitis, progressive vaccinia)
Key clinical trials
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox (PHASE2)
- Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC (PHASE4)
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (PHASE1)
- Evaluating the Human Immune Response to the JYNNEOS Vaccine (EARLY_PHASE1)
- A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine (PHASE1)
- MVA Post-Event: Administration Timing and Boost Study (PHASE1, PHASE2)
- Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia (PHASE3)
- JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: